1887

Abstract

Surveillance of the bacterial spectrum and antibiotic-resistance patterns of locally occurring uropathogens is essential to serve as a basis for empirical treatment of urinary tract infections (UTIs), as antibiotic-resistance rates may vary geographically with significant differences between countries and regions, and with time.

We retrospectively analysed all urine samples taken in the department of urology in a tertiary care hospital in Hungary from January 2004 to December 2015.

The five most commonly occurring bacteria were , , , and . Resistance of to ciprofloxacin increased significantly from 19 to 25 %. Although the resistance of against cephalosporins showed an increasing trend, it still remained generally low. However, resistance rates of to cephalosporins were very high, reaching 60 %, due to the high rate of extended-spectrum-β-lactamase-positive strains. We observed a significant increase in the rate of carbapenem-resistant

Fluoroquinolones cannot be recommended for empirical treatment in our region. Cephalosporins can be a good empirical choice for treating Gram-negative UTIs, but should be avoided when multi-drug resistant (MDR) bacteria are suspected. Increases in the rate of carbapenem-resistant and in the general rate of MDR bacteria, are both a very alarming trend. We recommend practising prudent antibiotic policy, preferably using antibiotics with the narrowest possible spectrum.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000498
2017-06-01
2020-08-09
Loading full text...

Full text loading...

/deliver/fulltext/jmm/66/6/788.html?itemId=/content/journal/jmm/10.1099/jmm.0.000498&mimeType=html&fmt=ahah

References

  1. Grabe M, Bjerklund-Johansen TE, Botto H et al. Guidelines on Urological Infections Arnhem:: European Association of Urology; 2015;https://uroweb.org/guidelines/ [accessed 01 December 2015]
    [Google Scholar]
  2. Wagenlehner FM, Naber KG. Treatment of bacterial urinary tract infections: presence and future. Eur Urol 2006;49:235–244 [CrossRef][PubMed]
    [Google Scholar]
  3. Çek M, Tandoğdu Z, Naber K, Tenke P, Wagenlehner F et al. Antibiotic prophylaxis in urology departments, 2005–2010. Eur Urol 2013;63:386–394 [CrossRef][PubMed]
    [Google Scholar]
  4. Wagenlehner FM, Bartoletti R, Cek M, Grabe M, Kahlmeter G et al. Antibiotic stewardship: a call for action by the urologic community. Eur Urol 2013;64:358–360 [CrossRef][PubMed]
    [Google Scholar]
  5. Johansen TE, Cek M, Naber KG, Stratchounski L, Svendsen MV et al. Hospital acquired urinary tract infections in urology departments: pathogens, susceptibility and use of antibiotics. data from the PEP and PEAP-studies. Int J Antimicrob Agents 2006;28:S91–S107[CrossRef]
    [Google Scholar]
  6. CLSI Performance Standards for Antimicrobial Susceptibility Testing Wayne, PA: Clinical and Laboratory Standards Institute; 2004;http://clsi.org/ [accessed 14 March 2016]
    [Google Scholar]
  7. EUCAST EUCAST MIC Breakpoint Tables Basel: European Committee on Antimicrobial Susceptibility Testing; 2011;www.eucast.org/ [accessed 12 March 2016]
    [Google Scholar]
  8. Hungarian National Nosocomial Surveillance System (National Epidemiology Centre). 2016;www.oek.hu/oek.web?nid=1070&pid=1 [accessed 02 April 2016]
  9. Shaifali I, Gupta U, Mahmood SE, Ahmed J. Antibiotic susceptibility patterns of urinary pathogens in female outpatients. N Am J Med Sci 2012;4:163–169 [CrossRef][PubMed]
    [Google Scholar]
  10. Elhanan G, Sarhat M, Raz R. Empiric antibiotic treatment and the misuse of culture results and antibiotic sensitivities in patients with community-acquired bacteraemia due to urinary tract infection. J Infect 1997;35:283–288 [CrossRef][PubMed]
    [Google Scholar]
  11. Tandogdu Z, Cek M, Wagenlehner F, Naber K, Tenke P et al. Resistance patterns of nosocomial urinary tract infections in urology departments: 8-year results of the Global Prevalence of Infections in Urology study. World J Urol 2014;32:791–801 [CrossRef][PubMed]
    [Google Scholar]
  12. Centers for Disease Control and Prevention Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009;58:256–260[PubMed]
    [Google Scholar]
  13. McCusker ME, Harris AD, Perencevich E, Roghmann MC. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis 2003;9:730–733 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000498
Loading
/content/journal/jmm/10.1099/jmm.0.000498
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error